Biodexa Pharmaceuticals (BDRX) EBIT Margin (2015 - 2020)

Biodexa Pharmaceuticals has disclosed EBIT Margin across 6 years of filings, most recently posting 13714.29% for Q4 2020.

• In Q4 2020, EBIT Margin fell 1121030.0% year-over-year to 13714.29%; the TTM figure through Dec 2020 stood at 1385.74% (down 112933.0% YoY), while the FY2023 annual figure was 2103.41%, down 82559.0% from the prior year.
• EBIT Margin came in at 13714.29% for Q4 2020 at Biodexa Pharmaceuticals, down from 10919.64% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 100.67% in Q4 2017 to a low of 13714.29% in Q4 2020.
• Average EBIT Margin over 5 years is 4628.93%, with a median of 1404.17% recorded in 2019.
• Year-over-year, EBIT Margin surged 21112 bps in 2016 and tumbled 1121030 bps in 2020.
• Over 5 years, EBIT Margin stood at 230.68% in 2016, then soared by 56 bps to 100.67% in 2017, then tumbled by 202 bps to 304.35% in 2018, then plunged by 723 bps to 2503.98% in 2019, then slumped by 448 bps to 13714.29% in 2020.
• Per Business Quant data, the three most recent EBIT Margin figures were 13714.29% in Q4 2020, 10919.64% in Q3 2020, and 2503.98% in Q4 2019.